Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies
暂无分享,去创建一个
[1] A. Drilon,et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.
[2] A. Drilon,et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.
[3] K. Bencardino,et al. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. , 2019 .
[4] A. Drilon. TRK inhibitors in TRK fusion-positive cancers. , 2019 .
[5] A. Laslop,et al. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries , 2019, ESMO Open.
[6] M. Barbacid. On the right TRK: from oncogene discovery to cancer therapeutics , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] M. Ladanyi,et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] P. V. Van Schil,et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] C. Wetmore,et al. Abstract CT030: STARTRK-NG: A phase 1/1b study of entrectinib in children and adolescents with advanced solid tumors and primary CNS tumors, with or without TRK, ROS1, or ALK fusions , 2017 .
[10] A. Drilon,et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). , 2017, Cancer discovery.
[11] A. Isacchi,et al. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor. , 2016, Journal of medicinal chemistry.
[12] R. Bosotti,et al. Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications , 2016, Molecular Cancer Therapeutics.
[13] R. Bosotti,et al. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer , 2015, Journal of the National Cancer Institute.
[14] S Senan,et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] Andrea Lombardi Borgia,et al. The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition , 2014, Molecular oncology.
[16] M. Barbacid,et al. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences , 1986, Nature.